Frontiers in medicine · 2026
Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Zebiao, Chen Jiongyu, Tang Lihua, Wang Jing, Yang Shuaibing, Wu Haituo, Zhou Li, Qin Qingsong, Wang Xiaojing
Аннотация
BACKGROUND: Uterine corpus endometrial carcinoma (UCEC) incidence rises globally, with >50% of advanced/recurrent patients showing poor response to immune checkpoint inhibitors due to inadequate biomarkers. Protein tyrosine kinase 6 (PTK6), aberrantly expressed in malignancies and linked to tumor progression, lacks defined clinical significance in UCEC.
METHODS: Multi-omics analysis utilized UCEC RNA-seq (TCGA/GEO) and proteomics (CPTAC). PTK6 protein interactors from STRING were used for functional enrichment analysis. Tumor microenvironment (TME) was assessed via ESTIMATE (stromal/immune scores), TIMER3 (immune infiltration), and TCIA (immunophenoscore, IPS). Immunohistochemistry (IHC) validation (n = 200) explored the prognostic value.
RESULTS: PTK6 was upregulated in UCEC (p < 0.001) with promoter hypomethylation (median β: 0.32 vs. normal 0.52, p < 0.001), highest in microsatellite instability-high (MSI-H) subtype, and correlated with tumor mutational burden (TMB). High PTK6 expression associated with worse overall survival (OS) in both entire cohort (HR = 2.065, 95% CI 1.060-4.203, p = 0.033) and MSI-H subtype (HR = 8.562, 95% CI 2.226-32.930, p = 0.0018). Exploratory analysis suggested low PTK6-linked reduced progression-free survival in POLE subtype (HR = 10.48, 95% CI 1.063-103.4, p = 0.044; wide CI suggests caution). PTK6-related genes were mainly involved in ERBB signaling, PD-1/PD-L1 immune checkpoint in cancers, and focal adhesion. Upregulated PTK6 was associated with an altered TME (increased neutrophils, decreased CD8+ T cells, reduced IPS; all p < 0.05). IHC confirmed PTK6 overexpression as an independent poor prognostic factor for OS (HR = 5.050, 95% CI 2.136-11.943, p < 0.001), associating with aggressive clinicopathological features (all p < 0.05).
CONCLUSION: PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.
METHODS: Multi-omics analysis utilized UCEC RNA-seq (TCGA/GEO) and proteomics (CPTAC). PTK6 protein interactors from STRING were used for functional enrichment analysis. Tumor microenvironment (TME) was assessed via ESTIMATE (stromal/immune scores), TIMER3 (immune infiltration), and TCIA (immunophenoscore, IPS). Immunohistochemistry (IHC) validation (n = 200) explored the prognostic value.
RESULTS: PTK6 was upregulated in UCEC (p < 0.001) with promoter hypomethylation (median β: 0.32 vs. normal 0.52, p < 0.001), highest in microsatellite instability-high (MSI-H) subtype, and correlated with tumor mutational burden (TMB). High PTK6 expression associated with worse overall survival (OS) in both entire cohort (HR = 2.065, 95% CI 1.060-4.203, p = 0.033) and MSI-H subtype (HR = 8.562, 95% CI 2.226-32.930, p = 0.0018). Exploratory analysis suggested low PTK6-linked reduced progression-free survival in POLE subtype (HR = 10.48, 95% CI 1.063-103.4, p = 0.044; wide CI suggests caution). PTK6-related genes were mainly involved in ERBB signaling, PD-1/PD-L1 immune checkpoint in cancers, and focal adhesion. Upregulated PTK6 was associated with an altered TME (increased neutrophils, decreased CD8+ T cells, reduced IPS; all p < 0.05). IHC confirmed PTK6 overexpression as an independent poor prognostic factor for OS (HR = 5.050, 95% CI 2.136-11.943, p < 0.001), associating with aggressive clinicopathological features (all p < 0.05).
CONCLUSION: PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.